Patients admitted to or visiting hospitals can develop multiple infections, which are known as hospital-acquired infections (HAIs), or, simply, hospital infections. These conditions generally spread within nursing homes, dialysis centers, rehabilitation centers, outpatient surgery centers, and hospitals. Various bacterial, fungal, and viral pathogens are the reason behind hospital infections. Moreover, intensive care units are also a common source of HAIs, which can be treated using different antimicrobial drugs. Some therapeutic drugs available for these diseases are CAZ AVI, Surotomycin, MK-3415A, and Ceftolozane.
The growing susceptibility of the neonatal population to various HAIs and booming pipeline of drugs for these conditions would lead to maasive growth in the hospital infection therapeutics market in the coming years. Moreover, the lack of skilled nursing staff in healthcare settings, especially in emerging economies, is a key factor making therapeutic drugs more important than ever. In many countries, these factors will offer pharmaceutical companies a happy headache regarding increasing their production capacity and marketing their offerings worldwide in the coming years.
According to P&S Intelligence, antibacterial drugs have been in the highest demand till now, and the scenario is unlikely to change in the near future. This is because most HAIs are caused by bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), central line-associated bloodstream infection (CLABSI), vancomycin-resistant Staphylococcus aureus (VRSA), Clostridium difficile infection, and catheter-associated urinary tract infections. Moreover, bacterial infections have been known for a long time, and they are easily curable via antibacterial agents, unlike viral ones, which have no real cure.
Other kinds of HAIs include hospital-acquired pneumonia (HAP) and surgical site infections. Among these, hospital-acquired pneumonia has the highest cases globally, also leading to the largest number of deaths in healthcare settings. As per studies, almost 33% of the deaths from infections in healthcare settings are attributed to HAP. In addition, cases of urinary tract infections will also increase in the coming years, thereby driving the demand for drugs for the hospitalized. Similarly, the increasing volume of surgeries is propelling the incidence of surgical site infections.
Moreover, the number of hospitals is rising worldwide, primarily due to the government efforts to make healthcare accessible to the masses. As per the World Bank, the number of hospital beds per 1,000 people around the world increased to 2.894 in 2017 from 2.462 in 2005. A higher number of hospital beds means a larger number of hospital patients, which translates into a higher incidence of various HAIs. Ultimately, it will increase the demand for therapeutic drugs in the coming years.
Over the last few years, North America has emerged as the hospital infection therapeutics market leader. The reason is the higher ratio of hospitals to the population of the region compared to other parts of the world. The surging population of the aging people in the continent and the increasing count of multi-drug-resistant microbial pathogens are also significant reasons leading to the rising demand for therapeutic drugs. APAC is also witnessing a rising demand for therapeutic drugs, especially in China and India, due to the growing prevalence of HAIs.
Thus, the increasing incidence HAIs, in part due to the rising number of healthcare settings globally, will drive the demand for therapeutic drugs in the coming years.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?